Validating Biomarkers for the Prodrome and Transition to Psychosis in Shanghai

描述(申请人提供)：“验证上海精神病前驱症状和向精神病过渡的生物标志物”7.项目摘要/摘要：识别精神分裂症的高危人群是制定精神分裂症早期干预和预防策略的核心。在世界范围内，主要由澳大利亚、欧洲和北美的研究人员(“北美前驱症状纵向研究/NAPLS”)领导的对处于假定前驱症状、临床高风险(CHR)阶段的人群的研究正在进行。在亚洲早期精神病网络中，台湾和新加坡已经开始解决假定为先兆人群的问题。据我们所知，我们是唯一一个与上海精神卫生中心(SMHC)MH093294合作进行CHR研究的小组(Fogarty/NIH，“将精神病先兆的调查扩大到不同的文化群体”)。初步研究已经开始，包括四个主要部分：a)使用前驱症状结构化访谈和前驱症状量表(SIPS/SOPS)对前驱受试者进行的临床评估(由R21的PI Li博士翻译成中文)；b)使用Matrics电池进行神经认知评估；c)耻辱，以及d)事件相关电位。此外，还将收集和储存血液样本，以供将来进行基因分析。我们目前的提案是为了响应RFA-AI-12-021：“美国-中国生物医学合作研究计划(R01)”，将通过大幅扩大样本，在SMHC建立和扩展R21，并引入磁共振成像的结构、DTI和静息状态测量。我们将与SMHC的研究人员合作，设计并启动一个可持续的CHR到中国的纵向研究计划。SMHC是世界卫生组织指定的精神健康研究中心，拥有出色的临床和生物医学研究技术资源，可以与美国团队合作开展一流的研究。我们的具体目标是：1.识别CRR与对照组的临床和生物标记物异常；2.复制NAPLS研究中对精神病算法的预测；3.证明随着转化为精神病，大脑异常增加。200名CHR和100名对照，年龄在15-45岁，将在基线上进行评估，并跟踪一年，结果估计有40名精神病转化者。估计保留率为75%，30名精神病患者，120名未精神病患者和75名对照组将在转换时或一年后通过广泛的临床和生物学措施进行评估。

DESCRIPTION (provided by applicant): "Validating Biomarkers for the Prodrome and Transition to Psychosis in Shanghai" 7. Project Summary/Abstract: The identification of people at risk of developing psychosis is central to the development of early intervention and prevention strategies for schizophrenia. There is a worldwide movement in the study of populations at the putatively prodromal, clinical high-risk (CHR) stage led mainly by researchers in Australia, Europe, and North America ("North American Prodrome Longitudinal Studies/NAPLS). Within the Asian Network for Early Psychosis, Taiwan and Singapore have started to address the putatively prodromal population. To our knowledge, we are the only group carrying out a CHR study, an R21 in collaboration with the Shanghai Mental Health Center (SMHC), MH093294 (Fogarty/NIH, "Broadening the Investigation of Psychosis Prodrome to Different Cultural Groups"). The preliminary study, which has already begun, contains four major components: a) clinical assessment of prodromal subjects using the Structured Interview for Prodromal Syndromes and Scale of Prodromal Symptoms (SIPS/SOPS) (translated into Chinese by the PI of the R21, Dr. Li); b) neurocognitive assessment with the MATRICS battery, c) stigma, and d) event related potentials. In addition, blood samples will be collected and stored for future genetic analyses. Our current proposal, in response to the RFA-AI-12-021: "U.S.-China Program for Biomedical Collaborative Research (R01)" will build upon and extend the R21 at the SMHC by expanding the sample substantially and bring in structural, DTI and resting state measures of magnetic resonance imaging (MRI). We will work collaboratively with researchers at the SMHC to design and initiate a sustainable CHR to psychosis longitudinal program of research in China. The SMHC, a World Health Organization designated research center for mental health, has excellent clinical and biomedical research technical resources that can carry out a first-rate study in collaboration with the US team. Our specific aims are to: 1. Identify clinical and biomarker abnormalities in CHR vs. Controls; 2. Replicate prediction of psychosis algorithms from the NAPLS study and; 3. Demonstrate increasing brain abnormalities with conversion to psychosis. Two hundred CHR and 100 controls, age 15-45, will be assessed at baseline and followed for one year, resulting in an estimated 40 converters to psychosis. With an estimated retention rate of 75%, 30 CHR who become psychotic, 120 who do not become psychotic and 75 controls will be assessed at conversion or 1 year follow-up with an extensive battery of clinical and biological measures.